Price-demand elasticity research

Providing evidence-based value pricing strategies to the pharmaceutical industry

Optimize performance against competition both within and outside your therapy class

Inpharmation’s Pharma-Specific™ price-demand elasticity research has been developed by experts to overcome the challenges faced when running traditional pharmaceutical pricing research:
  • Price-elasticity demand research goes far beyond traditional pricing research, to give you powerful strategic recommendations based on a number of different pricing landscape scenarios.
  • Running pharmaceutical price-elasticity demand research when you have a limited number of respondents, in this case limited payers, requires efficient survey techniques.
  • Inpharmation’s validated pharmaceutical price-elasticity demand research methods are subject to up to 79% less error than traditional pricing research methods*.
*Independent comparison of two direct pricing methodologies
%
Reduction in error compared to traditional pricing methodologies.*

Traditional payer research is often inflexible and cannot adjust to a large number of different market conditions, for example different numbers of competitors, different competitor pricing strategies and different possibilities for competitor price evolutions.

Inpharmation’s Pharma-Specific price-demand elasticity research has been designed to provide strategic pricing insights, to understand how competitor pricing strategies affect your brand:
  • Pharmaceutical lifecycle pricing: Inpharmation’s Pharma-Specific price-demand elasticity research is specific for all stages of your pharmaceutical brand lifecycle pricing, whether you are developing a pricing strategy pre-launch, need to run in-market price optimization due to competitor price tactics or need to optimize prices in the light of further indication launches.
  • Going beyond the brand: Inpharmation’s Pharma-Specific price-demand elasticity research can investigate supra-brand pharma pricing effects, investigating whether brand (and biosimilar) pricing strategy can impact usage of the therapeutic class or treatment mechanism.
  • Scenario analysis: Inpharmation’s decades of systems modelling experience means project-specific options can include scenario analysis engines and system-modelling simulators.
%
Of the top-20 global pharma companies use Inpharmation’s pricing solutions.

"Europe's most respected pharma forecasting & pricing specialist consultancy."

Centre for Executive Leadership

Evidence-based approach to price-demand elasticity research

Inpharmation’s Pharma-Specific price-demand elasticity research is the premier solution to pharmaceutical pricing and market questions when your business question needs a fine-tuned quantitative answer. This is because Inpharmation’s research techniques are structured in a precise way, and can be compared rigorously against other structured techniques. In this way, the best techniques can be selected and deployed to help recommend a value-based pricing strategy.

Unstructured interviews cannot be scientifically tested as no two unstructured interviews are ever the same. (Although, we do know from a vast body of empirical research that unstructured judgments produce much worse predictions than structured techniques.)

Inpharmation deploys a range of evidence-based quantitative pharmaceutical pricing and market access research techniques and these can be used throughout the development of a pharmaceutical product. In fact, 70% of the top-20 global pharma companies already use Inpharmation’s pricing solutions.

Download the full Case Study by filling in the form:

By clicking on the “Submit Request” button you are providing consent for us to store your data and contact you. You may withdraw your consent at any time by instructing us at .

View our Privacy Policy for more information.

Please note that Inpharmation literature and case study materials constitute Inpharmation intellectual property and are intended for the pharmaceutical industry. Inpharmation is under no obligation to distribute these materials to non-pharmaceutical industry employees or competitors.

Scroll Top